Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › MDxHealth Prostate Cancer Test Gains New York State Approval

MDxHealth Prostate Cancer Test Gains New York State Approval

Nov 26, 2018
|
staff reporter

NEW YORK (GenomeWeb) – MDxHealth said today that the New York State Department of Health has approved its SelectMDx test for prostate cancer. The approval completes MDxHealth's state licensing requirements for SelectMDx, allowing the firm to offer the liquid biopsy test in all 50 US states.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

What's Popular?

In Cancer

  1. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  2. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

  3. Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

  4. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  5. UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.